Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PH-HFpEF)

NCT05983250 is registered in ClinicalTrials.gov with Tenax Therapeutics, Inc. as lead sponsor.

NCT NCT05983250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05983250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PH-HFpEF)
Lead sponsor
Tenax Therapeutics, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 10, 2024
Completion date
October 30, 2028
Enrollment
230 (estimated)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary hypertension